← All Alvotech filings

Alvotech 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
ALVO
Alvotech
20-F: Alvotech's 2024 Annual Report: Revenue Growth Offset by Significant Losses
Alvotech's 2024 annual report reveals increased product revenue but also significant net losses, highlighting the challenges of biosimilar development and commercialization.
NASDAQ
ALVO
Alvotech
20-F: Alvotech's 2023 Financial Results: Revenue Growth Offset by Increased Operating Losses
Alvotech's 2023 financial results show increased product revenue but also significant operating losses, highlighting the challenges of biosimilar development and commercialization.